Article
Oncology
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro
Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.
Article
Oncology
Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Summary: In patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, daratumumab plus lenalidomide and dexamethasone significantly improved overall survival and progression-free survival with no new safety concerns.
Article
Medicine, General & Internal
Graham H. Jackson, Charlotte Pawlyn, David A. Cairns, Ruth M. de Tute, Anna Hockaday, Corinne Collett, John R. Jones, Bhuvan Kishore, Mamta Garg, Cathy D. Williams, Kamaraj Karunanithi, Jindriska Lindsay, Alberto Rocci, John A. Snowden, Matthew W. Jenner, Gordon Cook, Nigel H. Russell, Mark T. Drayson, Walter M. Gregory, Martin F. Kaiser, Roger G. Owen, Faith E. Davies, Gareth J. Morgan
Summary: The study evaluated the efficacy and safety of using Carfilzomib in combination with other drugs to treat newly diagnosed multiple myeloma patients. Patients receiving Carfilzomib combination therapy were more likely to achieve better partial response and had significantly longer progression-free survival compared to the control group.
Article
Medicine, General & Internal
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Spicka, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Mace, Thomas Martin
Summary: The study showed that the addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.
Article
Hematology
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Jan Maciej Zaucha, Damian Mikulski, Olga Czabak, Oscar B. Lahoud, Andrew Stefka, Benjamin A. Derman, Andrzej J. Jakubowiak
Summary: This study analyzed the recovery of polyclonal immunoglobulin in patients with multiple myeloma after autologous stem cell transplant. It found that continuous therapy can lead to at least partial recovery of polyclonal immunoglobulin, which is a positive prognostic marker.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Peter A. Forsberg, Adriana C. Rossi, Angelique Boyer, Roger N. Pearse, Karen A. Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, Scott Ely, Leora Boussi, John N. Allan, Morton Coleman, Ruben Niesvizky, Tomer M. Mark
Summary: The study evaluated a new treatment regimen for multiple myeloma called Car-BiRd and found that it can achieve similar outcomes with reduced toxicities compared to standard treatment regimens. The results showed a high overall response rate in newly diagnosed MM patients and suggest that the sequential Car-BiRd regimen is an effective and safe approach for upfront treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Saad Z. Usmani, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Maria Gavriatopoulou, Albert Oriol, Neil Rabin, Ajay Nooka, Ming Qi, Meral Beksac, Andrzej Jakubowiak, Bifeng Ding, Anita Zahlten-Kumeli, Akeem Yusuf, Meletios Dimopoulos
Summary: This study compares the efficacy and safety of carfilzomib, daratumumab, and dexamethasone (KdD) with carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma. The results demonstrate a clear and sustained progression-free survival benefit with KdD over Kd, indicating that KdD is emerging as the standard of care for these patients.
Article
Oncology
Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Mueller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, Nicola Giesen
Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.
Article
Oncology
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. B. Lahoud, Heather J. J. Landau, David J. J. Chung, Gunjan L. L. Shah, Michael Scordo, Sergio A. A. Giralt, Alexander Lesokhin, Saad Z. Z. Usmani, Ola Landgren, Neha Korde
Summary: This retrospective study compared the efficacy and safety of VRd and KRd as induction regimens. The results showed that KRd was associated with improved progression-free survival (PFS) and event-free survival (EFS) compared to VRd, with a more significant improvement observed in high-risk patients.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Anna Astarita, Giulia Mingrone, Lorenzo Airale, Marco Cesareo, Anna Colomba, Cinzia Catarinella, Dario Leone, Francesca Gay, Sara Bringhen, Franco Veglio, Alberto Milan, Fabrizio Vallelonga
Summary: The purpose of this study was to compare the incidence and time of onset of cardiovascular complications induced by Carfilzomib-dexamethasone and Carfilzomib-lenalidomide-dexamethasone in patients with multiple myeloma. The results showed that the Carfilzomib-dexamethasone group had a higher incidence and earlier onset of cardiovascular events, while the Carfilzomib-lenalidomide-dexamethasone group was more likely to develop signs of cardiac and vascular damage.
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M. Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld
Summary: In this ongoing phase III trial, daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death compared to pomalidomide and dexamethasone alone, demonstrating that it could be considered a new treatment option for relapsed or refractory multiple myeloma patients.
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Hematology
Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cecile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hebraud, Jill Corre, Michel Attal
Summary: The study shows that using carfilzomib, lenalidomide, and dexamethasone in combination with transplant treatment for eligible patients with newly diagnosed multiple myeloma can produce rapid and deep responses, with an acceptable safety profile. Close monitoring of cardiovascular adverse events is necessary.
Article
Oncology
Elisabetta Antonioli, Sofia Pilerci, Irene Attucci, Gabriele Buda, Alessandro Gozzetti, Veronica Candi, Federico Simonetti, Maria Livia Del Giudice, Sara Ciofini, Michela Staderini, Sara Grammatico, Alessandra Buzzichelli, Maria Messeri, Monica Bocchia, Sara Galimberti, Alessandro. M. M. Vannucchi
Summary: This multicenter prospective observational study evaluated the efficacy of KRd combination therapy for multiple myeloma. The results showed an overall response rate of 95% and a median progression-free survival of 36 months. Patients who underwent autologous stem cell transplantation and achieved at least very good partial remission had longer progression-free survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Joanna Zaleska, Paulina Kwasnik, Magdalena Paziewska, Joanna Purkot, Aleksandra Szabelak, Mateusz Jurek, Natalia Masny, Izabela Dziatkiewicz, Bartosz Pronobis-Szczylik, Agnieszka Piebiak, Agnieszka Szymczyk, Katarzyna Jarosz-Chudzik, Lukasz Bolkun, Katarzyna Kozlowska, Jaroslaw Piszcz, Edyta Subocz, Janusz Halka, Michal Bator, Elzbieta Kalicinska, Tomasz Wrobel, Lidia Usnarska-Zubkiewicz, Justyna Rybka, Izabela Deren-Wagemann, Marta Szyca-Smieszniak, Jaroslaw Dybko, Iwona Hus, Bartosz Pula, Edyta Cichocka, Marcin Rymko, Dorota Zdunczyk, Mateusz Ziarkiewicz, Grzegorz Wladyslaw Basak, Lars Bullinger, Krzysztof Giannopoulos
Summary: Multiple myeloma and chronic lymphocytic leukemia patients have increased susceptibility to COVID-19 due to impaired immune function. This study evaluated the efficacy of mRNA COVID-19 vaccines in these patients and found that vaccination can induce specific CD8+ T cell responses, but they do not correlate positively with serological responses.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Joanna Gora-Tybor, Aleksandra Golos, Damian Mikulski, Grzegorz Helbig, Tomasz Sacha, Krzysztof Lewandowski, Joanna Niesiobedzka-Krezel, Maria Bieniaszewska, Hubert Wysoglad, Olga Grzybowska-Izydorczyk, Ilona Seferynska, Marta Sobas, Maria Czyzewska, Agnieszka Michalska, Waldemar Sawicki, Malwina Mazur, Marek Hus, Ewa Bodzenta, Magdalena Olszewska-Szopa, Martyna Wlodarczyk, Elzbieta Patkowska, Wojciech Swistek, Krzysztof Jamroziak
Summary: In this study, predictors of response to ruxolitinib therapy in Polish myelofibrosis patients were investigated. Leukocytosis < 25 G/L, reticulin fibrosis MF 1, shorter time from MF diagnosis to ruxolitinib start, and platelets >150 G/L were correlated with better response to ruxolitinib. Identifying predictive factors for ruxolitinib response is important for identifying patients who are less likely to respond.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Marco Dicanio, Matteo Giaccherini, Alyssa Clay-Gilmour, Angelica Macauda, Juan Sainz, Mitchell J. Machiela, Malwina Rybicka-Ramos, Aaron D. Norman, Agata Tyczynska, Stephen J. Chanock, Torben Barington, Shaji K. Kumar, Parveen Bhatti, Wendy Cozen, Elizabeth E. Brown, Anna Suska, Eva K. Haastrup, Robert Z. Orlowski, Marek Dudzinski, Ramon Garcia-Sanz, Marcin Kruszewski, Joaquin Martinez-Lopez, Katia Beider, Elzbieta Iskierka-Jazdzewska, Matteo Pelosini, Sonja Berndt, Malgorzata Razny, Krzysztof Jamroziak, S. Vincent Rajkumar, Artur Jurczyszyn, Annette Juul Vangsted, Pilar Garrido Collado, Ulla Vogel, Jonathan N. Hofmann, Mario Petrini, Aleksandra Butrym, Susan L. Slager, Elad Ziv, Edyta Subocz, Graham G. Giles, Niels Frost Andersen, Grzegorz Mazur, Marzena Watek, Fabienne Lesueur, Michelle A. T. Hildebrandt, Daria Zawirska, Lene Hyldahl Ebbesen, Herlander Marques, Federica Gemignani, Charles Dumontet, Judit Varkonyi, Gabriele Buda, Arnon Nagler, Agnieszka Druzd-Sitek, Xifeng Wu, Katalin Kadar, Nicola J. Camp, Norbert Grzasko, Rosalie G. Waller, Celine Vachon, Federico Canzian, Daniele Campa
Summary: The aim of this study was to identify novel pleiotropic variants involved in multiple myeloma (MM) risk. Through analysis of 28,684 single nucleotide polymorphisms (SNPs), DNAJB4-rs34517439-A was found to be associated with an increased risk of developing MM.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Fruzsina Kosa, Tereza Necasova, Martin Spacek, Krzysztof Giannopoulos, Iwona Hus, Tereza Jurkova, Eva Koritakova, Marika Chrapava, Martina Novackova, Ivana Katinova, Denisa Krejci, Adam Jujka, Zoltan Matrai, Istvan Valyi-Nagy, Tadeusz Robak, Michael Doubek
Summary: This study is the first to analyze a large sample of chronic lymphocytic leukemia (CLL) patients across multiple countries, aiming to evaluate the incidence, types, and key prognostic factors of secondary malignancies, as well as the impact on overall survival. The study analyzed data from 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland, and observed that 33.7% of treated patients developed secondary malignancies during the study. The study concludes that secondary malignancies in CLL patients are an underestimated burden and deserve deeper considerations in decision making.
Review
Pharmacology & Pharmacy
Tadeusz Robak, Pawel Robak
Summary: This article summarizes recent achievements in the treatment of relapsed and refractory hairy cell leukemia. The growing understanding of HCL biology has led to the development of several new targeted drugs, which have shown promising efficacy in early clinical trials.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Letter
Oncology
Tadeusz Robak, Jaroslaw D. Kasprzak, Dorota Jesionek-Kupnicka, Michal Soin, Pawel Robak
LEUKEMIA & LYMPHOMA
(2023)
Review
Oncology
Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
Summary: This review summarizes the research on the biological causes of ENKTL and the identification of new therapeutic targets and biomarkers, which may enable a personalized medicine approach towards ENKTL therapy.
Article
Hematology
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G. Karrison, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison M. Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas Bisneto, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J. Slade, Nathan Singh, Naushee Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Summary: Checkpoint inhibitor therapy with anti-PD-1 antibodies is not effective as a salvage strategy for most patients after CAR-T, particularly among those relapsing early after CAR-T. Alternative approaches are needed to improve post-CAR-T outcomes.
Review
Biochemistry & Molecular Biology
Magdalena Witkowska, Agata Majchrzak, Pawel Robak, Anna Wolska-Washer, Tadeusz Robak
Summary: PI3K & delta; inhibitors are novel agents used to treat B-cell malignancies by inhibiting enzymes in the PI3K/AKT/mTOR pathway. Idelalisib is an effective inhibitor for B-cell lymphoid malignancies.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Review
Medicine, Research & Experimental
Agata Tyczynska, Jan Zaucha
Summary: Several novel drugs, including monoclonal and bispecific antibodies, immunomodulatory agents, and newer-generation proteasome inhibitors, have been introduced for multiple myeloma treatment in the past decade. While the drugs have been incorporated into current treatment recommendations based on randomized clinical trials, the recommendations for patients over 75 are indirectly proposed due to lack of conclusive data. This paper reviews crucial studies and outlines the current treatment recommendations for these patients, highlighting the safety and efficacy of different regimens, including the breakthrough drug daratumumab.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Meeting Abstract
Oncology
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Lidia Usnarska-Zubkiewicz, Olga Czabak, Andrew Stefka, Ken Jiang, Benjamin Derman, Andrzej Jakubowiak
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)